Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 6Breast Neoplasms 5Prostatic Neoplasms 4Hematologic Neoplasms 4Colorectal Neoplasms 4Melanoma 3Lung Neoplasms 3Pancreatic Neoplasms 2Malignant Solid Neoplasm 2Leukemia, Myeloid, Acute 2Hematopoietic and Lymphatic System Neoplasm 2Head and Neck Neoplasms 2COVID-19 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spondylitis, Ankylosing 1Speech 1Seroma 1Rectal Neoplasms 1Psoriasis 1Progressive Metastatic Castrate Resistant Prostate Cancer 1Postoperative Complications 1Peritoneal Neoplasms 1Parotid Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Specimen Handling 5Biopsy 5Magnetic Resonance Spectroscopy 4Cyclophosphamide 3sodium-iodide symporter 2ruxolitinib 2duvelisib 2cemiplimab 2X-Rays 2Vincristine 2Prednisone 2Photons 2Immunoglobulin G 2Etoposide 2Doxorubicin 2Disulfides 2prednylidene 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Stem Cell Transplantation 1Standard of Care 1Practice Guidelines as Topic 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Nivolumab 1Melphalan 1Leukapheresis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × Standard of Care × 30 days × Clear all
NCT06724237 2026-05-15

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Eastern Cooperative Oncology Group

Phase 3 Recruiting
294 enrolled
Lymphoid

Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡